Cargando…

Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences

We examined the effect of a dietary seaweed extract—sulfated xylorhamnoglucuronan (SXRG84)—on individuals with inflammatory skin conditions. A subgroup analysis of a larger trial was undertaken, where 44 participants with skin conditions were enrolled in a double-blind placebo-controlled crossover d...

Descripción completa

Detalles Bibliográficos
Autores principales: Roach, Lauren A., Meyer, Barbara J., Fitton, J. Helen, Winberg, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381427/
https://www.ncbi.nlm.nih.gov/pubmed/37504910
http://dx.doi.org/10.3390/md21070379
_version_ 1785080441140674560
author Roach, Lauren A.
Meyer, Barbara J.
Fitton, J. Helen
Winberg, Pia
author_facet Roach, Lauren A.
Meyer, Barbara J.
Fitton, J. Helen
Winberg, Pia
author_sort Roach, Lauren A.
collection PubMed
description We examined the effect of a dietary seaweed extract—sulfated xylorhamnoglucuronan (SXRG84)—on individuals with inflammatory skin conditions. A subgroup analysis of a larger trial was undertaken, where 44 participants with skin conditions were enrolled in a double-blind placebo-controlled crossover design. Subjects ingested either SXRG84 extract (2 g/day) for six weeks and placebo for six weeks, or vice versa. At baseline, six- and twelve-weeks inflammatory markers and the gut microbiota were assessed, as well as skin assessments using the dermatology quality of life index (DQLI), psoriasis area severity index (PASI) and visual analogue scales (VAS). There were significant differences at weeks six and twelve for pro-inflammatory cytokines IFN-γ (p = 0.041), IL-1β (p = 0.030), TNF-α (p = 0.008) and the anti-inflammatory cytokine IL-10 (p = 0.026), determined by ANCOVA. These cytokines were all significantly higher at six weeks post placebo compared to twelve weeks post placebo followed by SXRG84 treatment. A total of 23% of participants reported skin improvements, as measured by VAS (mean difference 3.1, p = 0.0005) and the DQLI score (mean difference -2.0, p = 0.049), compared to the ‘non-responders’. Thus, the ingestion of SXRG84 for 6 weeks reduced inflammatory cytokines, and a subset of participants saw improvements.
format Online
Article
Text
id pubmed-10381427
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103814272023-07-29 Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences Roach, Lauren A. Meyer, Barbara J. Fitton, J. Helen Winberg, Pia Mar Drugs Article We examined the effect of a dietary seaweed extract—sulfated xylorhamnoglucuronan (SXRG84)—on individuals with inflammatory skin conditions. A subgroup analysis of a larger trial was undertaken, where 44 participants with skin conditions were enrolled in a double-blind placebo-controlled crossover design. Subjects ingested either SXRG84 extract (2 g/day) for six weeks and placebo for six weeks, or vice versa. At baseline, six- and twelve-weeks inflammatory markers and the gut microbiota were assessed, as well as skin assessments using the dermatology quality of life index (DQLI), psoriasis area severity index (PASI) and visual analogue scales (VAS). There were significant differences at weeks six and twelve for pro-inflammatory cytokines IFN-γ (p = 0.041), IL-1β (p = 0.030), TNF-α (p = 0.008) and the anti-inflammatory cytokine IL-10 (p = 0.026), determined by ANCOVA. These cytokines were all significantly higher at six weeks post placebo compared to twelve weeks post placebo followed by SXRG84 treatment. A total of 23% of participants reported skin improvements, as measured by VAS (mean difference 3.1, p = 0.0005) and the DQLI score (mean difference -2.0, p = 0.049), compared to the ‘non-responders’. Thus, the ingestion of SXRG84 for 6 weeks reduced inflammatory cytokines, and a subset of participants saw improvements. MDPI 2023-06-27 /pmc/articles/PMC10381427/ /pubmed/37504910 http://dx.doi.org/10.3390/md21070379 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Roach, Lauren A.
Meyer, Barbara J.
Fitton, J. Helen
Winberg, Pia
Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences
title Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences
title_full Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences
title_fullStr Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences
title_full_unstemmed Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences
title_short Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences
title_sort oral supplementation with algal sulphated polysaccharide in subjects with inflammatory skin conditions: a randomised double-blind placebo-controlled trial and baseline dietary differences
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381427/
https://www.ncbi.nlm.nih.gov/pubmed/37504910
http://dx.doi.org/10.3390/md21070379
work_keys_str_mv AT roachlaurena oralsupplementationwithalgalsulphatedpolysaccharideinsubjectswithinflammatoryskinconditionsarandomiseddoubleblindplacebocontrolledtrialandbaselinedietarydifferences
AT meyerbarbaraj oralsupplementationwithalgalsulphatedpolysaccharideinsubjectswithinflammatoryskinconditionsarandomiseddoubleblindplacebocontrolledtrialandbaselinedietarydifferences
AT fittonjhelen oralsupplementationwithalgalsulphatedpolysaccharideinsubjectswithinflammatoryskinconditionsarandomiseddoubleblindplacebocontrolledtrialandbaselinedietarydifferences
AT winbergpia oralsupplementationwithalgalsulphatedpolysaccharideinsubjectswithinflammatoryskinconditionsarandomiseddoubleblindplacebocontrolledtrialandbaselinedietarydifferences